Press coverage about LivaNova (NASDAQ:LIVN) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. LivaNova earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.0227248783493 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of LivaNova (NASDAQ:LIVN) traded down $1.97 during trading on Tuesday, hitting $80.31. The company had a trading volume of 269,339 shares, compared to its average volume of 323,940. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. LivaNova has a twelve month low of $45.67 and a twelve month high of $88.56. The firm has a market capitalization of $3,966.85, a PE ratio of 68.64, a PEG ratio of 2.27 and a beta of 0.61.
LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.78 earnings per share. research analysts predict that LivaNova will post 3.24 earnings per share for the current fiscal year.
In related news, Director Hugh M. Morrison sold 1,830 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total transaction of $161,040.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alfred J. Novak sold 2,000 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,830 shares of company stock worth $494,770. Corporate insiders own 0.28% of the company’s stock.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.